Back to search

United Kingdom· GB-APID-41446411000001108

Orgovyx 120mg tablets

A relugolix product containing relugolix, registered in United Kingdom by Accord-UK Ltd. The same ATC class is registered in 15 of our 19 countries.

ATC L02BX04

Checked against NHS dm+d (United Kingdom) on

Informational only — not a medical device.

SOURCE REGISTER · GBNHS dm+d (United Kingdom)normalisedOrgovyx 120mg tabletsATCL02BX04REGISTER NO.GB-APID-4144641100000…PACKS LISTED4CHECKEDSeptember 13, 2026

Where it is registered

Relugolix is registered in 15 of 19 countries.

Countries holding a registration under ATC L02BX04 (relugolix), each read from that country’s own register.

  • This record: United Kingdom, from NHS dm+d (United Kingdom)
  • 10 of them publish a price we can compare per daily dose

Relugolix · ATC L02BX04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of relugolix costs, country by country.

Normalised to the WHO defined daily dose (0.12 g), the median price runs from $3.40 in France to $9.83 in Italy — a ×2.9 gap.

  • 4 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Relugolix · price per daily dose (0.12 g)

USD · FX 28 Sept 2026

  • IT Italy$9.83
  • ES Spain$7.69
  • CH Switzerland$6.03
  • FR France$3.40
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

NHS dm+d (United Kingdom)
Active substance
Relugolix
Manufacturer
Accord-UK Ltd
Country
United Kingdom (GB)
ATC code
L02BX04
ATC class
Relugolix
Defined daily dose
0.12 g, O
Reimbursed
Not published by this register
Source register
NHS dm+d (United Kingdom)
Last checked
September 13, 2026

Packs & prices · 4

  • gtin
    05012617002358
  • gtin
    5012617002358
  • gtin
    5012617003676
  • gtin
    05012617003676

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

168 interactions on record for relugolix.

Graded by severity as the source publishes them — 52 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Relugolix · interactions on record

168 records

  • 52 severe
  • 101 moderate
  • 15 minor

Most severe, free to view

  • PapaverineA03AD01severe
  • DolasetronA04AA04severe
  • RolapitantA04AD14severe
  • FidaxomicinA07AA12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Relugolix in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All relugolix products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Orgovyx
  • Liechtenstein · Orgovyx
  • Norway · Orgovyx

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ee667795-24fd-4dbf-b9cf-a3ac353ea231
GET /v1/drugs/ee667795-24fd-4dbf-b9cf-a3ac353ea231?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "apid": "41446411000001108",
  "desc": "Orgovyx 120mg tablets (Accord-UK Ltd)",
  "form": "Oral tablet",
  "vpid": "41462611000001101",
  "source": "dmd",
  "vtm_id": "1144511002",
  "strength": "120 mg",
  "substance": "Relugolix",
  "ingredient": "Relugolix",
  "supplier_code": "18471011000001103"
}

See everything about relugolix.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.